These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1329651)

  • 1. Comparison of antiviral assay methods using cell-free and cell-associated varicella-zoster virus.
    Shiraki K; Ochiai H; Namazue J; Okuno T; Ogino S; Hayashi K; Yamanishi K; Takahashi M
    Antiviral Res; 1992 Jun; 18(2):209-14. PubMed ID: 1329651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS.
    Talarico CL; Phelps WC; Biron KK
    J Virol; 1993 Feb; 67(2):1024-33. PubMed ID: 8380452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of BV-araU and acyclovir on varicella-zoster virus replication with various length and timing of drug exposure.
    Machida H; Nishitani M; Ashida N
    Microbiol Immunol; 1994; 38(2):109-15. PubMed ID: 8041297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
    Andrei G; De Clercq E; Snoeck R
    Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
    Yokota T; Konno K; Mori S; Shigeta S; Kumagai M; Watanabe Y; Machida H
    Mol Pharmacol; 1989 Aug; 36(2):312-6. PubMed ID: 2549386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug susceptibilities of isolates of varicella-zoster virus in a clinical study of oral brovavir.
    Machida H; Nishitani M
    Microbiol Immunol; 1990; 34(4):407-11. PubMed ID: 2163486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic anti-varicella-zoster virus activity of interferon-alpha 2a and acyclovir in corneal cells.
    Punda-Polić V; O'Brien WJ; Taylor JL
    Zentralbl Bakteriol; 1999 Apr; 289(2):203-10. PubMed ID: 10360320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a DNA probe assay with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella-zoster virus to penciclovir and acyclovir.
    Standring-Cox R; Bacon TH; Howard BA
    J Virol Methods; 1996 Jan; 56(1):3-11. PubMed ID: 8690764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes.
    Koyano S; Suzutani T; Yoshida I; Azuma M
    Antimicrob Agents Chemother; 1996 Apr; 40(4):920-3. PubMed ID: 8849252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the selectivity of anti-varicella-zoster virus nucleoside analogues.
    Machida H; Nishitani M; Watanabe Y; Yoshimura Y; Kano F; Sakata S
    Microbiol Immunol; 1995; 39(3):201-6. PubMed ID: 7603364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral potencies of BV-araU and related nucleoside analogues against varicella-zoster virus in different cell lines.
    Machida H; Ijichi K; Ohta A; Honda M; Niimura M
    Microbiol Immunol; 1990; 34(11):959-65. PubMed ID: 1965323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV.
    Hasegawa T; Kurokawa M; Yukawa TA; Horii M; Shiraki K
    Antiviral Res; 1995 Jun; 27(3):271-9. PubMed ID: 8540749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
    Sakuma T
    Antimicrob Agents Chemother; 1984 Jun; 25(6):742-6. PubMed ID: 6331298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of DNA synthesis in varicella-zoster virus-infected cells by BV-araU.
    Machida H; Watanabe Y
    Microbiol Immunol; 1991; 35(2):139-45. PubMed ID: 1653394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against thymidine kinase negative strains of varicella-zoster virus.
    Kawai H; Yoshida I; Suzutani T
    Microbiol Immunol; 1993; 37(11):877-82. PubMed ID: 8295566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of varicella-zoster virus to thymidine analogues.
    Machida H
    Biken J; 1986 Mar; 29(1):1-6. PubMed ID: 3022708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations.
    Mercier-Darty M; Boutolleau D; Lepeule R; Rodriguez C; Burrel S
    Antiviral Res; 2018 Mar; 151():20-23. PubMed ID: 29337163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two bromovinyl nucleoside analogs, 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and E-5-(2-bromovinyl)-2'-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication.
    Lin JC; Machida H
    Antimicrob Agents Chemother; 1988 Jul; 32(7):1068-72. PubMed ID: 2847639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-l-1-[5-(E-2-bromovinyl)-2-(hydroxymethyl)-1,3-(dioxolan-4-yl)] uracil (l-BHDU) prevents varicella-zoster virus replication in a SCID-Hu mouse model and does not interfere with 5-fluorouracil catabolism.
    De C; Liu D; Zheng B; Singh US; Chavre S; White C; Arnold RD; Hagen FK; Chu CK; Moffat JF
    Antiviral Res; 2014 Oct; 110():10-9. PubMed ID: 25051026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary assays for monitoring susceptibility of varicella-zoster virus resistance to antivirals.
    Perrier M; Désiré N; Deback C; Agut H; Boutolleau D; Burrel S
    J Virol Methods; 2016 Jul; 233():10-4. PubMed ID: 26994966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.